Opposing effects of dexamethasone, agrin and sugammadex on functional innervation and constitutive secretion of IL-6 in in vitro innervated primary human muscle cells

Neuroscience Letters

Volumn 549, Issue , 2013, Pages 186-190

  Rezonja, K ^a   Lorenzon, P ^b   Mars, T ^c  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^b UNIVERSITY OF TRIESTE   (Italy)

^c UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Agrin; Dexamethasone; Interleukin 6; Neuromuscular junction; Sugammadex

Indexed keywords

AGRIN; DEXAMETHASONE; INTERLEUKIN 6; LACTATE DEHYDROGENASE; SUGAMMADEX;

ANIMAL TISSUE; ARTICLE; COCULTURE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG ANTAGONISM; DRUG CYTOTOXICITY; EMBRYO; EXPLANT; HUMAN; HUMAN CELL; IN VITRO STUDY; MUSCLE CELL; MUSCLE INNERVATION; MYOTUBE; NEUROMUSCULAR TRANSMISSION; NONHUMAN; PRIORITY JOURNAL; RAT; SKELETAL MUSCLE; SPINAL CORD; SYNAPTOGENESIS;

AGRIN; DEXAMETHASONE; INTERLEUKIN 6; NEUROMUSCULAR JUNCTION; SUGAMMADEX;

AGRIN; ANIMALS; DEXAMETHASONE; DRUG INTERACTIONS; GAMMA-CYCLODEXTRINS; HUMANS; INTERLEUKIN-6; MUSCLE, SKELETAL; MYOBLASTS; NEUROMUSCULAR JUNCTION; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84880737109     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2013.06.014     Document Type: Article

References (42)

1. Ahlbeck K., Fredriksson K., Rooyackers O., Maback G., Remahl S., Ansved T., Eriksson L., Radell P. Signs of critical illness polyneuropathy and myopathy can be seen early in the ICU course. Acta Anaesthesiol. Scand. 2009, 53:717-723.
2. Askanas V., Kwan H., Alvarez R., Engel King W., Kobayashi T., Martinuzzi A., Hawkins E. De-novo neuromuscular junction formation on human muscle fibres cultured in monolayer and innervated by foetal rat spinal cord: ultrastructural and ultrastructural-cytochemical studies. J. Neurocytol. 1987, 16:523-537.
3. Baeza-Raja B., Munoz-Canoves P. p38 MAPK-induced nuclear factor-kappaB activity is required for skeletal muscle differentiation: role of interleukin-6. Mol. Biol. Cell 2004, 15:2013-2026.
4. Barnes P.J. How corticosteroids control inflammation: Quintiles Prize Lecture 2005. Br. J. Pharmacol. 2006, 148:245-254.
5. Bom A., Bradley M., Cameron K., Clark J.K., Van Egmond J., Feilden H., MacLean E.J., Muir A.W., Palin R., Rees D.C., Zhang M.Q. A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host. Angew. Chem. Int. Ed. Engl. 2002, 41:266-270.
6. Braun S., Askanas V., Engel W.K., Ibrahim E.N. Long-term treatment with glucocorticoids increases synthesis and stability of junctional acetylcholine receptors on innervated cultured human muscle. J. Neurochem. 1993, 60:1929-1935.
7. Burden S.J. Building the vertebrate neuromuscular synapse. J. Neurobiol. 2002, 53:501-511.
8. Carballo-Jane E., Pandit S., Santoro J.C., Freund C., Luell S., Harris G., Forrest M.J., Sitlani A. Skeletal muscle: a dual system to measure glucocorticoid-dependent transactivation and transrepression of gene regulation. J. Steroid Biochem. Mol. Biol. 2004, 88:191-201.
9. Dalkara T., Onur R. Facilitatory effects of dexamethasone on neuromuscular transmission. Exp. Neurol. 1987, 95:116-125.
10. Daniels M.P. The role of agrin in synaptic development, plasticity and signaling in the central nervous system. Neurochem. Int. 2012, 61:848-853.
11. Dengler R., Rudel R., Warelas J., Birnberger K.L. Corticosteroids and neuromuscular transmission: electrophysiological investigation of the effects of prednisolone on normal and anticholinesterase-treated neuromuscular junction. Pflügers Arch. 1979, 380:145-151.
12. Denzer A.J., Gesemann M., Schumacher B., Ruegg M.A. An amino-terminal extension is required for the secretion of chick agrin and its binding to extracellular matrix. J. Cell Biol. 1995, 131:1547-1560.
13. El Azab S.R., Rosseel P.M., de Lange J.J., Groeneveld A.B., van Strik R., van Wijk E.M., Scheffer G.J. Dexamethasone decreases the pro- to anti-inflammatory cytokine ratio during cardiac surgery. Br. J. Anaesth. 2002, 88:496-501.
14. El-Helou V., Proulx C., Gosselin H., Clement R., Mimee A., Villeneuve L., Calderone A. Dexamethasone treatment of post-MI rats attenuates sympathetic innervation of the infarct region. J. Appl. Physiol. 2008, 104:150-156.
15. Fahim M.A. Chronic corticosterone treatment-induced ultrastructural changes at rat neuromuscular junction. Anat. Rec. 1995, 242:424-431.
16. Giniatullin A.R., Grishin S.N., Giniatullin R.A. Effects of glucocorticoids and epinephrine on the modulatory action of purines in the frog neuromuscular junction. Neurophysiology 2002, 34:133-134.
17. Hamrahian A.H., Oseni T.S., Arafah B.M. Measurements of serum free cortisol in critically ill patients. N. Engl. J. Med. 2004, 350:1629-1638.
18. Henzi I., Walder B., Tramèr M.R. Dexamethasone for the prevention of postoperative nausea and vomiting: a quantitative systematic review. Anesth. Analg. 2000, 90:186-194.
19. Horinouchi H., Kumamoto T., Kimura N., Ueyama H., Tsuda T. Myosin loss in denervated rat soleus muscle after dexamethasone treatment. Pathobiology 2005, 72:108-116.
20. Kobayashi T., Askanas V. Acetylcholine receptors and acetylcholinesterase accumulate at the nerve-muscle contacts of de novo grown human monolayer muscle cocultured with fetal rat spinal cord. Exp. Neurol. 1985, 88:327-335.
21. Kobayashi T., Askanas V., Engel W.K. Human muscle cultured in monolayer and cocultured with fetal rat spinal cord: importance of dorsal root ganglia for achieving successful functional innervation. J. Neurosci. 1987, 7:3131-3141.
22. Mars T., Yu K.-J., Tang X.-M., Miranda A.F., Grubic Z., Cambi F., King M.P. Differentiation of glial cells and motor neurons during the formation of neuromuscular junctions in co-cultures of rat spinal cord explant and human muscle. J. Comp. Neur. 2001, 438:239-251.
23. Mars T., King M.P., Miranda A.F., Walker W.F., Mis K., Grubic Z. Functional innervation of cultured human skeletal muscle proceeds by two modes with regard to agrin effects. Neuroscience 2003, 118:87-97.
24. Massa R., Carpenter S., Holland P., Karpati G. Loss and renewal of thick myofilaments in glucocorticoid-treated rat soleus after denervation and reinnervation. Muscle Nerve 1992, 15:1290-1298.
25. McMahan U.J. The agrin hypothesis. Cold Spring Harb. Symp. Quant. Biol. 1990, 55:407-418.
26. McPhee S.J. Disorders of the adrenal cortex. Pathophysiology of Disease 2000, 500-528. McGraw-Hill, New York. V.R. Lingappa, W.F. Ganong, J.D. Lange, S.J. McPhee (Eds.).
27. Menconi M., Fareed M., O'Neal P., Poylin V., Wei W., Hasselgren P.O. Role of glucocorticoids in the molecular regulation of muscle wasting. Crit. Care Med. 2007, 35:S602-S608.
28. Murphy G.S., Brull S.J. Residual neuromuscular block: lessons unlearned. Part I: definitions, incidence, and adverse physiologic effects of residual neuromuscular block. Anesth. Analg. 2010, 111:120-128.
29. Naguib M. Sugammadex: another milestone in clinical neuromuscular pharmacology. Anesth. Analg. 2007, 104:575-581.
30. Oakley R.H., Cidlowski J.A. Cellular processing of the glucocorticoid receptor gene and protein: new mechanisms for generating tissue-specific actions of glucocorticoids. J. Biol. Chem. 2011, 286:3177-3184.
31. Pegan K., Matkovic U., Mars T., Mis K., Pirkmajer S., Brecelj J., Grubic Z. Acetylcholinesterase is involved in apoptosis in the precursors of human muscle regeneration. Chem. Biol. Interact. 2010, 187:96-100.
32. Podbregar M., Lainscak M., Prelovsek O., Mars T. Cytokine response of cultured skeletal muscle cells stimulated with proinflammatory factors depends on differentiation stage. Sci. World J. 2013, 2013:617170.
33. Prelovsek O., Mars T., Jevsek M., Podbregar M., Grubic Z. High dexamethasone concentration prevents stimulatory effects of TNF-alpha and LPS on IL-6 secretion from the precursors of human muscle regeneration. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2006, 291:R1651-R1656.
34. Roberts R.J., Welch S.M., Devlin J.W. Corticosteroids for prevention of postextubation laryngeal edema in adults. Ann. Pharmacother. 2008, 42:686-691.
35. Sieck G.C., Van Balkom R.H., Prakash Y.S., Zhan W.Z., Dekhuijzen P.N. Corticosteroid effects on diaphragm neuromuscular junctions. J. Appl. Physiol. 1999, 86:114-122.
36. Srivastava A., Hunter J.M. Reversal of neuromuscular block. Br. J. Anaesth. 2009, 103:115-129.
37. Stair C., Fernandez-Bustamante A. Sugammadex, the first selective relaxant binding agent for neuromuscular block reversal. Drugs Today (Barc) 2012, 48:405-413.
38. Van Staa T.P., Leufkens H.G., Abenhaim L., Begaud B., Zhang B., Cooper C. Use of oral corticosteroids in the United Kingdom. QJM 2000, 93:105-111.
39. Washington T.A., White J.P., Davis J.M., Wilson L.B., Lowe L.L., Sato S., Carson J.A. Skeletal muscle mass recovery from atrophy in IL-6 knockout mice. Acta Physiol. (Oxf) 2011, 202:657-669.
40. Zhang C., Li Y., Wu Y., Wang L., Wang X., Du J. Interleukin-6/signal transducer and activator of transcription 3 (STAT3) pathway is essential for macrophage infiltration and myoblast proliferation during muscle regeneration. J. Biol. Chem. 2013, 288:1489-1499.
41. Zhang M.-Q. Drug-specific cyclodextrins: the future of rapid neuromuscular block reversal. Drugs Future 2003, 28:347-354.
42. Zwiers A., van den Heuvel M., Smeets J., Rutherford S. Assessment of the potential for displacement interactions with sugammadex: a pharmacokinetic-pharmacodynamic modelling approach. Clin. Drug Investig. 2011, 31:101-111.